We have also shown that the distribution of cancer sites appears to vary according to anti-TIF1-Ab status, with female anti-TIF1-Ab-positive patients at increased risk of ovarian cancer [14, 15]. This evidence concerns the gene TRIM24 and ovarian cancer.